MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 05-08-2025
Regulus Therapeutics ROA Ratio 2011-2026 | RGLS
Annual ROA Ratio Regulus Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -97.68 | -60.63 | -40.62 | -41.83 | -44.18 | -174.42 | -92.41 | -81.3 | -39.51 | -33.05 | -15.17 | -16.82 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -15.17 | -174.42 | -61.47 |
Quarterly ROA Ratio Regulus Therapeutics
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -53.47 | -33.02 | -53.74 | -59.47 | -64.94 | -56.08 | -56.08 | -48.72 | -46.02 | -37.75 | -44.43 | -64.48 | -63.29 | -47.32 | -50.84 | -34.85 | -41.13 | -41.83 | -49.94 | -58.78 | -52.22 | -44.18 | -63.22 | -87.11 | -124.78 | -174.41 | -162.32 | -145.88 | -124.06 | -92.41 | -93.73 | -92.78 | -85.96 | -81.3 | -66.53 | -56.36 | -50.31 | -39.51 | -47.32 | -43.82 | -35.89 | -33.05 | -21.69 | -17.74 | -16.73 | -15.17 | -20.25 | -23.98 | -20.52 | -16.82 | -14.87 | -11.82 | -9.31 | -4.7 | -2.44 | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.44 | -174.41 | -54.53 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Amgen
AMGN
|
8.51 | $ 349.36 | 2.75 % | $ 188 B | USA |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
1.96 | $ 12.67 | 2.82 % | $ 3.97 B | USA |
 |
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
-218.41 | - | - | $ 8.42 M | USA |
 |
argenx SE
ARGX
|
-14.32 | $ 784.45 | 2.48 % | $ 25 B |  Niderland |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Arcutis Biotherapeutics
ARQT
|
-3.73 | $ 24.45 | 5.07 % | $ 3.11 B | USA |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
AVROBIO
AVRO
|
12.03 | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
0.11 | - | - | $ 96.9 B |  Britain |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-48.81 | $ 1.47 | 8.17 % | $ 391 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alterity Therapeutics Limited
ATHE
|
-31.06 | $ 3.83 | 1.86 % | $ 9.21 B |  Australia |
 |
BioNTech SE
BNTX
|
65.02 | $ 91.3 | 1.87 % | $ 27.2 B | Germany |
 |
CymaBay Therapeutics
CBAY
|
-24.24 | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
-10.92 | $ 2.72 | 5.84 % | $ 17.1 M | USA |
 |
Burford Capital Limited
BUR
|
5.51 | $ 4.59 | 0.88 % | $ 742 M | Britain |
 |
Avid Bioservices
CDMO
|
-41.82 | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
-79.06 | - | - | $ 1.41 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Cabaletta Bio
CABA
|
-101.68 | $ 3.07 | - | $ 308 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-86.4 | $ 3.08 | 1.65 % | $ 6.7 B | Israel |
 |
Checkpoint Therapeutics
CKPT
|
-752.78 | - | - | $ 169 M | USA |
 |
Cerus Corporation
CERS
|
-7.04 | $ 1.93 | 4.89 % | $ 368 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
-77.89 | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
-48.42 | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
-73.85 | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-254.37 | - | -45.71 % | $ 1.2 M | Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-36.63 | - | -4.36 % | $ 27 M | USA |
 |
Cellectar Biosciences
CLRB
|
-145.48 | $ 2.82 | 2.55 % | $ 7.36 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-41.16 | - | - | $ 2.18 B | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
2.77 | - | - | $ 2.02 B | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Cyclerion Therapeutics
CYCN
|
-31.93 | $ 3.47 | -0.29 % | $ 8.74 M | USA |